What is Barrington Research's Estimate for ANIK Q1 Earnings?

Anika Therapeutics, Inc. (NASDAQ:ANIK - Free Report) - Barrington Research issued their Q1 2026 earnings per share estimates for Anika Therapeutics in a research note issued to investors on Thursday, March 13th. Barrington Research analyst M. Petusky anticipates that the biotechnology company will post earnings per share of ($0.16) for the quarter. Barrington Research has a "Outperform" rating and a $20.00 price target on the stock. The consensus estimate for Anika Therapeutics' current full-year earnings is ($0.84) per share. Barrington Research also issued estimates for Anika Therapeutics' Q2 2026 earnings at ($0.14) EPS, Q3 2026 earnings at ($0.09) EPS, Q4 2026 earnings at ($0.09) EPS and FY2027 earnings at ($0.45) EPS.

Separately, StockNews.com raised Anika Therapeutics from a "hold" rating to a "buy" rating in a report on Thursday, March 13th.

Anika Therapeutics Price Performance

NASDAQ ANIK traded down $0.36 during trading on Monday, hitting $15.60. The company's stock had a trading volume of 39,153 shares, compared to its average volume of 67,652. The company has a market cap of $228.40 million, a PE ratio of -2.33 and a beta of 0.95. The business's 50 day simple moving average is $16.91 and its 200-day simple moving average is $19.31. Anika Therapeutics has a fifty-two week low of $14.95 and a fifty-two week high of $29.12.

Remove Ads

Anika Therapeutics (NASDAQ:ANIK - Get Free Report) last issued its quarterly earnings results on Wednesday, March 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.01) by ($0.13). The business had revenue of $30.60 million during the quarter, compared to analyst estimates of $29.00 million. Anika Therapeutics had a negative return on equity of 2.22% and a negative net margin of 59.40%.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of ANIK. R Squared Ltd purchased a new position in shares of Anika Therapeutics in the fourth quarter worth about $27,000. Aquatic Capital Management LLC purchased a new position in shares of Anika Therapeutics in the fourth quarter worth about $42,000. Tower Research Capital LLC TRC raised its stake in shares of Anika Therapeutics by 412.4% in the fourth quarter. Tower Research Capital LLC TRC now owns 2,890 shares of the biotechnology company's stock worth $48,000 after purchasing an additional 2,326 shares during the last quarter. Wells Fargo & Company MN raised its stake in shares of Anika Therapeutics by 31.1% in the fourth quarter. Wells Fargo & Company MN now owns 7,421 shares of the biotechnology company's stock worth $122,000 after purchasing an additional 1,759 shares during the last quarter. Finally, Public Employees Retirement System of Ohio purchased a new position in shares of Anika Therapeutics in the fourth quarter worth about $137,000. 91.53% of the stock is currently owned by hedge funds and other institutional investors.

About Anika Therapeutics

Anika Therapeutics, Inc, a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally.